The biennial Crossroad for BioTransfer will provide a unique opportunity for health-sector businesses to forge partnerships with three research-intensive institutions and leading researchers and innovators.
The event will showcase 40 high-impact technologies, from the National Research Council Canada, through its Biotechnology Research Institute (NRC-BRI) and Institute for Biological Sciences (NRC-IBS); Montreal Excellerator, representing McGill University and the McGill University Health Centre; and Gestion Univalor, limited partnership, representing Université de Montréal and affiliated hospital centres.
BioTransfer will enable biotechnology and pharmaceutical companies, entrepreneurs and the venture capital community to access intellectual property with high commercial potential. The intensive one-day event, to take place May 5 at the NRC-BRI, will give companies the opportunity to identify and invest in technologies to advance their drug-discovery capabilities and enhance their product pipelines.
The presentations will focus on technologies related to novel biopharmaceuticals, small-molecule therapeutics, platforms for drug discovery and processes of manufacturing. The program also includes keynote presentations by national and international business leaders and provides networking forums. Pre-arranged meetings may be booked online for one-on-one meetings during the event.
Crossroad for BioTransfer 2009; May 5, 8 a.m.-5 p.m., NRC Biotechnology Research Institute, 6100 Royalmount Ave. Registration fee is $150. For more information, visit www.biotransfer.ca